安序源冲刺港交所：融合IC、BT与AI技术，打造新一代电化学检测平台

Core Viewpoint - Axbio International Limited is set to go public on the Hong Kong Stock Exchange, focusing on advanced platforms for life sciences research and clinical applications, integrating IC, biotech, and AI technologies [2]. Product Development - Axbio's product pipeline includes a microarray analyzer, two EL-NGS gene sequencers, and various diagnostic reagent kits, with key products like AxiLona EL-100 and AxiLona AXP-100 [3][4]. - The AxiLona EL-100 is one of the few molecular diagnostic products in China capable of electrochemical, multi-target, rapid, low-cost, and integrated biomolecular detection, having completed clinical trials and received regulatory approval [4]. - AxiLona AXP-100 is the world's first EL-NGS gene sequencer, utilizing advanced semiconductor biochips, and AxiLona AXP-1000 is in the design phase, expected to have ten times the throughput of AXP-100 [5]. Market Opportunity - The protein detection market in China and globally is projected to grow to 94 billion yuan and 62.9 billion USD by 2033, respectively, with compound annual growth rates of 6.2% and 5.2% [4]. - Axbio aims to expand the clinical application of AxiLona EL-100 by adding protein detection capabilities to capture market opportunities [4]. Financial Overview - Axbio's valuation before the IPO is approximately 347.5 million USD, with funds raised intended for further development and commercialization of core products, as well as operational and general corporate purposes [6].